ARTICLE | Distillery Therapeutics
Therapeutics: Toll-like receptor 3 (TLR3)
April 2, 2015 7:00 AM UTC
In vitro and mouse studies suggest a selective TLR3 agonist could boost the effectiveness of cancer immunotherapy. The TLR3 agonist consisted of a region of the dsRNA measles virus linked to a phospho...